Disc Medicine, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

IRON$84.64+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$44,080	$50,334	$136,917	$124,416
Selling, general and administrative	20,081	17,362	61,843	44,636
Total operating expenses	64,161	67,696	198,760	169,052
Loss from operations	(64,161)	(67,696)	(198,760)	(169,052)
Other income (expense), net:
Interest income	6,454	6,412	19,879	20,349
Interest expense	(1,714)	(917)	(3,466)	(2,724)
Other (expense) income	(5)	(18)	5	47
Total other income (expense), net	4,735	5,477	16,418	17,672
Loss before income taxes	(59,426)	(62,219)	(182,342)	(151,380)
Income tax expense	(109)	(102)	(229)	(273)
Net loss	$(59,535)	$(62,321)	$(182,571)	$(151,653)
Net loss per share, basic and diluted	$(1.53)	$(1.77)	$(4.72)	$(4.39)
Weighted-average common shares outstanding, basic and diluted	38,904,676	35,178,691	38,695,405	34,516,134
Comprehensive loss:
Net loss	$(59,535)	$(62,321)	$(182,571)	$(151,653)
Other comprehensive (loss) income:
Foreign currency translation adjustments	3	—	(9)	(1)
Unrealized (loss) gain on marketable securities	(1,165)	445	(3,726)	430
Total other comprehensive (loss) income	(1,162)	445	(3,735)	429
Comprehensive loss	$(60,697)	$(61,876)	$(186,306)	$(151,224)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.